| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 3/6 |
| Financial Health | 3/6 |
| Dividends | 4/6 |
Cencora, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$224.75 |
| 52 Week High | US$228.35 |
| 52 Week Low | US$151.94 |
| Beta | 0.46 |
| 1 Month Change | -0.067% |
| 3 Month Change | 13.00% |
| 1 Year Change | 49.83% |
| 3 Year Change | 128.17% |
| 5 Year Change | 223.15% |
| Change since IPO | 907.85% |
Recent News & Updates
Recent updates
Shareholder Returns
| ABG | DE Healthcare | DE Market | |
|---|---|---|---|
| 7D | 0% | 5.4% | 1.7% |
| 1Y | 49.8% | 0.6% | 2.3% |
Return vs Industry: ABG exceeded the German Healthcare industry which returned 0.6% over the past year.
Return vs Market: ABG exceeded the German Market which returned 2.3% over the past year.
Price Volatility
| ABG volatility | |
|---|---|
| ABG Average Weekly Movement | 3.6% |
| Healthcare Industry Average Movement | 6.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.1% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: ABG has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine ABG's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2001 | 44,000 | Steve Collis | www.cencora.com |
Cencora, Inc. sources and distributes pharmaceutical products. The company’s U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.
Cencora, Inc. Fundamentals Summary
| ABG fundamental statistics | |
|---|---|
| Market cap | €44.28b |
| Earnings (TTM) | €1.74b |
| Revenue (TTM) | €253.60b |
25.4x
P/E Ratio0.2x
P/S RatioIs ABG overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ABG income statement (TTM) | |
|---|---|
| Revenue | US$271.58b |
| Cost of Revenue | US$262.43b |
| Gross Profit | US$9.15b |
| Other Expenses | US$7.28b |
| Earnings | US$1.87b |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 01, 2024
| Earnings per share (EPS) | 9.37 |
| Gross Margin | 3.37% |
| Net Profit Margin | 0.69% |
| Debt/Equity Ratio | 450.3% |
How did ABG perform over the long term?
See historical performance and comparison